Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1660-1667

  Fizazi, K ^a   Jenkins, C ^b   Tannock, Ian F ^c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Med Ed RMC   (United Kingdom)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

ADT; de novo metastatic; Docetaxel; Hormone naive; Prostate

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; CABAZITAXEL; DOCETAXEL; DOXORUBICIN; ENZALUTAMIDE; ESTRAMUSTINE; GONADORELIN AGONIST; KETOCONAZOLE; ORTERONEL; VINBLASTINE; ANTINEOPLASTIC AGENT; GONADORELIN; TAXOID;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; CANCER PATIENT; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HAZARD RATIO; HEALTH CARE QUALITY; HUMAN; INFECTION; LIVER DYSFUNCTION; LUNG EMBOLISM; METASTATIC HORMONE SENSITIVE PROSTATE CANCER; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SHORT COURSE THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LOCALIZATION; AGONISTS; BONE NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; MALE; ORCHIECTOMY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; SECONDARY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; STANDARD OF CARE; TAXOIDS;

EID: 84941709876     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv245     Document Type: Review

References (37)

1. Wu JN, Fish KM, Evans CP et al. No improvement noted in overall or causespecific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2013; 120(6): 818-823.
2. Center MM, Jemal A, Lortet-Tieulent J et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61(6): 1079-1092.
3. Cullen J, Elsamanoudi S, Brassell SA et al. The burden of prostate cancer in Asian nations. J Carcinog 2012; 11: 7.
4. Patrikidou A, Loriot Y, Eymard J-C et al. Who dies from prostate cancer? Prostate Cancer Prostatic Dis 2014; 17(4): 348-352.
5. Sweeney C, Carducci MA, Eisenberger MA et al. Chemohormonal therapy versus hormonal therapy for hormone naive newly metastatic prostate cancer: ECOG-led randomized trial. Ann Oncol 2014; (Suppl 4): Abstr 7560.
6. Gravis G, Fizazi K, Joly F et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14(2): 149-158.
7. Ahmed M, Li L-C. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 2013; 20(4): 362-371.
8. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502-1512.
9. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26(2): 242-245.
10. Petrylak DP, Tangen CM, Hussain MHA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513-1520.
11. Gravis G, Boher J-M, Joly F et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (Pca): long-term analysis of the GETUG-AFU-15 phase III trial. J Clin Oncol 2015; (GU suppl): abstr 140.
12. Sweeney C, Chen Y-H, Carducci MA et al. Impact on overall survival with chemohormonal therapy versus hormone therapy for hormone-sensitive newly metastatic prostate cancer: an ECOG-led phase III randomized trial. J Clin Oncol 2014; 32(5s): abstr LBA2.
13. Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol 2014; 65(6): 1198-1204.
14. Harris WP, Mostaghel EA, Nelson PS, Montgomery RB. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6(2): 76-85.
15. van Soest RJ, van Royen ME, de Morrée ES et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49(18): 3821-3830.
16. Mezynski J, Pezaro C, Bianchini D et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for crossresistance? Ann Oncol 2012; 23(11): 2943-2947.
17. Nakouzi Al N, Le Moulec S, Albiges L et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014; 66: e71-e72.
18. Payne H, Bahl A, Mason M et al. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012; 110(5): 658-667.
19. Droz J-P, Aapro M, Balducci L et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15(9): e404-e414.
20. Stone P, Hardy J, Huddart R et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36(9): 1134-1141.
21. Nguyen PL, Alibhai SMH, Basaria S et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67(5): 825-836.
22. Loriot Y, Fizazi K. Taxanes: still a major weapon in the armamentarium against prostate cancer. Eur Urol 2013; 63(6): 983-985.
23. Gerritse FL, Meulenbeld HJ, Roodhart JML et al. Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer 2013; 49(15): 3176-3183.
24. Fizazi K, Abrahamsson P-A, Ahlgren G et al. Achievements and perspectives in prostate cancer phase 3 trials from Genitourinary Research Groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 2015; 67(5): 904-912.
25. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036-1042.
26. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7): 419-424.
27. Hussain M, Tangen CM, Berry DL et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368(14): 1314-1325.
28. Millikan RE, Wen S, Pagliaro LC et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26(36): 5936-5942.
29. Tait C, Moore D, Hodgson C et al. Quantification of skeletal metastases in castrateresistant prostate cancer predicts progression-free and overall survival. BJU Int 2014; 114(6b): E70-E73.
30. Gravis G, Boher J-M, Fizazi K et al. Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the Glass Model and development of a novel simplified prognostic model. Eur Urol 2014 Sep 29 [epub ahead of print], doi: 10.1016/j.eururo.2014.09.022.
31. James ND, Spears MR, Clarke NW et al. Survival with newly diagnosed metastatic prostate cancer in the 'docetaxel era': data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67(6): 1028-1038.
32. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57(2): 229-233.
33. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253-265.
34. Mercader M, Sengupta S, Bodner BK et al. Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 2007; 99(1): 60-67.
35. Ioannidis J. Why most published research findings are false. PLoS Med 2005; 2 (8): e124.
36. Templeton AJ, Vera-Badillo FE, Wang L et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24(12): 2972-2977.
37. Gravis G, Marino P, Joly F et al. Patients self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUGAFU 15). Eur J Cancer 2014; 50(5): 953-962.